MAZE Company Profile and Key Details

MAZE has shown sold momentum, gaining 10.33% over the past week and 59.44% over the past quarter, though year-to-date performance is up 7.02%. Short-term trend indicators are bearishly aligned (SMA20 -0.54%, SMA50 5.89%, SMA200 71.51%). The stock’s 14-day RSI is 52.47 (neutral), while the ATR of 2.89 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -6.92% below its high and over 583.16% above its low. Average 10-day trading volume of 839.54 thousand shares is in line with the 3-month average of 875.71 thousand, indicating normal recent market interest.

Maze Therapeutics, Inc. (NASDAQ:MAZE) closed at $27.17 USD, gaining $0.59 (2.22%) from the previous close of $26.58. The stock is currently mid-range between its 52-week high and low $8.24 and $53.65. With a market capitalization of about $1.50 billion, Maze Therapeutics, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.50). Key stats such as the average daily volume over the past year has been around 871.34 thousand shares, in line with its 52-week average. Headquartered in South San Francisco, CA, Maze Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jason V. Coloma, the company employs approximately 125 people and listed since January 31, 2025. Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States.

Maze Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.86. This means the shares are trading above this model’s fair value.

Maze Therapeutics, Inc. has 43.85 million shares outstanding. The public float is 16.19 million shares, elevated short interest at 4.95% of float. This equals 1.78 million shares. The short ratio is 11.44 days. Institutional investors hold 94.19% of the float. Insiders own 5.9%. Bachrodt Amy holds 12.96 thousand shares, Dandekar Atul has 10.50 thousand shares and Sohn Catherine A. has 0.00 shares. Over the past six months, insider transactions show net selling. They sold 106.36 thousand shares across 20 transactions.

Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 15 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $110.00 to $17.00. The high target offers 313.84% upside. The low target suggests -36.04% downside. The mean target is $51.27. This offers 92.89% upside. Maze Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended March 25, 2026, missed forecasts by -10.96%. The prior quarter beat by -10.81%. Over the last six quarters, Apple has recorded several small beats. These include -4171.11% in March 31, 2025.

Maze Therapeutics, Inc. trades at a P/E ratio of -8.64, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.19 trading at moderately above to book value. The P/FCF stands at -12.92, also below market averages.

Maze Therapeutics, Inc. (NASDAQ:MAZE) shares are flat 7.02% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Maze Therapeutics, Inc. trading at a premium to the broader market with a P/E of -8.64. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $47.08, suggesting 77.13% upside. Our AI forecast model points to short-term weakness (-31.53% over two weeks), a medium-term rise (25.17% over three months), and a longer-term gain (131.11% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Maze Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -31.53%, with price expected at $18.20 by May 14, 2026, within a range of $12.25 to $24.23 3-Month Outlook: Projected rise of 25.17%, reaching $33.27 by July 29, 2026, with a range of $32.65 to $33.83. 1-Year Outlook: Projected gain of 131.11%, with price at $61.43 by April 30, 2027, within a range of $59.15 to $63.78.